Daniel A. Arber

1 month ago | nature.com | Mithun Vinod Shah |Kevin Hung |Anmol Baranwal |Aref Al-Kali |Antoine Saliba |dong chen | +18 more

AbstractThe World Health Organization (WHO-5) and International Consensus Classification (ICC) acknowledge the poor prognosis of TP53-mutated (TP53mut) myeloid neoplasm (MN). However, there are substantial differences between the two classifications that may lead to under- or overestimation of the prognostic risk. We retrospectively applied WHO-5 and ICC to 603 MN cases harboring TP53mut (variant allele frequency, VAF ≥ 2%).

Mar 3, 2025 | nature.com | Daniel A. Arber |Ayalew Tefferi |Alessandro Vannucchi |Tiziano Barbui

AbstractA lively discussion persists regarding the diagnostic criteria for essential thrombocythemia (ET), primary myelofibrosis (PMF) and polycythemia vera (PV), particularly in relation to early/pre-fibrotic myelofibrosis (pre-PMF), a disease entity initially introduced in 2001 by the 3rd edition of the World Health Organization (WHO) classification. The definition and criteria used to diagnose pre-PMF have been progressively modified over time.